Stopped losing weight on Mounjaro? Here's what's actually going on

You've been on Mounjaro a few months and the scales haven't moved in weeks

You check the number every morning. It was dropping steadily, then, somewhere around month two or three, it stopped. The pen is still in the fridge door, you're still injecting every Sunday, appetite is still noticeably lower than before. And yet nothing is shifting.

This is a plateau, and it is expected. Research into tirzepatide, including the SURMOUNT-1 trial published in the New England Journal of Medicine, showed that weight loss across thousands of participants was not linear. Most people lose quickly in the first eight to twelve weeks, then the rate slows. A period of near-zero change, lasting a few weeks, is part of how the body responds to sustained energy deficit, not a warning sign. Understanding how weight loss typically unfolds on Mounjaro can make these pauses feel less alarming.

What's happening physiologically is that as your body gets lighter, it needs fewer calories to function. Metabolic adaptation means the deficit created at your starting weight is smaller now. Mounjaro continues suppressing appetite and slowing gastric emptying (the mechanisms are still active) but the arithmetic of energy balance has shifted. The plateau is the body catching up with the medicine, not the medicine giving up.

What tends to drive a plateau on Mounjaro specifically

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only treatment of its kind licensed in the UK for weight management, as the NHS tirzepatide page notes. It works on two appetite-related pathways simultaneously, which is part of why its trial results are stronger than older GLP-1 medicines. But no medicine overrides all of human physiology.

Several things commonly contribute to a plateau: the body's adaptive thermogenesis (your metabolism running slightly cooler to conserve energy), a gradual relaxation of the dietary changes that were working early on, and the fact that lower body weight itself means smaller calorie burns during activity. Sleep disruption and stress also raise cortisol, which can slow fat loss even when food intake is controlled.

Dose is another factor. The starting dose of 2.5mg exists to let the body adjust gradually, it is not the therapeutic target. Most people see stronger appetite suppression and continued weight loss as they titrate upward. If you have been at 2.5mg or 5mg for several months without a dose review, that conversation with your prescriber is overdue. You can read more about when weight loss typically slows or stops on Mounjaro for a clearer picture of the expected timeline.

It is also worth checking practical things. Are you still rotating injection sites between your abdomen, thigh and upper arm? Repeated injections into the same spot can affect absorption. Is the pen stored correctly at 2–8°C? The Patient Information Leaflet covers the permitted room-temperature window; the pen should not be left in a hot car or exposed to direct light.

Whether stopping Mounjaro is the right answer depends on more than the number on the scales

Some people ask whether the plateau means they should stop treatment altogether. That is a clinical decision, not something to make based on a few static weeks. NICE guidance on tirzepatide (TA1026) states that if someone has not achieved at least 5% weight loss after six months at the highest dose they can tolerate, the prescriber should review whether continuing is appropriate. But a temporary plateau well before that point is a very different situation.

The question of whether it's safe to stop Mounjaro after reaching your goal is one our prescribers field regularly. The short answer is that weight tends to return after stopping, because the mechanisms the medicine was providing are no longer there. That doesn't mean staying on it indefinitely is always the plan, it means the decision needs thought and clinical input, not a solo call made after a frustrating week on the scales.

If you are on a plateau that has lasted more than four to six weeks, speak to your prescriber. At nume, every repeat order includes a clinical review before dispatch, so your prescriber is already looking at your progress, not just reissuing the same pen automatically.

What you can do right now, before your next clinical review

There are things within your control that genuinely shift plateaus. Protein intake matters more than most people realise, as tirzepatide reduces overall hunger, it can be easy to eat very little, including too little protein, which slows metabolism and muscle retention further. Keeping protein adequate (roughly 1.2–1.6g per kg of body weight daily is a commonly cited range, though your prescriber or a dietitian can give you a personal figure) helps preserve muscle mass while fat is lost.

Resistance activity is the other underused tool. Cardio burns calories in the moment; strength training raises resting metabolic rate over time. Neither needs to be intense at first. A brisk walk, two short sessions with weights per week, and consistent sleep are not dramatic interventions, but combined with a dose review, they often restart progress.

For broader context on what the treatment involves and how people typically respond, the Mounjaro treatment overview covers the full picture, including eligibility and the titration schedule. And if you are still at an early stage and wondering when results typically begin, the first notable changes usually come between weeks two and eight, with the most significant losses following dose increases.

Mounjaro is a prescription medicine, and the decisions around dose, duration and stopping all sit with your prescriber. If you have not yet started treatment and want to understand whether it could be right for you, our free consultation is the place to begin, a GPhC-registered prescriber reviews every application the same day.